MOTS-c Peptide: What the New FDA Policy Means for Access
A mitochondrial-derived peptide once found only in research labs may soon be available by prescription. Here is what the science-and the law-actually say.
MOTS-c is a 16-amino-acid peptide encoded by mitochondrial DNA that helps cells adapt to metabolic stress and has reduced obesity and insulin resistance in mouse studies. Although early research hints at benefits for weight management, diabetes and bone health, no human safety studies have been published, and MOTS-c is not FDA-approved. A new October 28 2026 FDA enforcement-discretion policy allows state-licensed 503A pharmacies to compound MOTS-c for individual patients under strict conditions, but the policy does not equal FDA approval and can be ignored by state boards. Rx.com plans to offer prescription compounded MOTS-c through U.S.-licensed providers and a 503A pharmacy (coming soon).
- The MOTS-c peptide is produced from the mitochondrial 12S rRNA and contains exactly 16 amino acids (Zheng et al., 2023).
- In mice, daily MOTS-c prevented high-fat-diet weight gain and improved insulin sensitivity, pointing to anti-obesity potential (Lee et al., 2015).
- FDA staff reviewers told the Pharmacy Compounding Advisory Committee that no human safety studies of MOTS-c were located, so risk is unknown (federalregister.gov).
- The October 2026 interim policy lets 503A pharmacies compound MOTS-c for patient-specific prescriptions, but states may choose not to follow it.
- MOTS-c from Rx.com is coming soon; until then, research-use-only MOTS-c products remain unregulated and fall outside the policy.
What MOTS-c Is-a quick definition
MOTS-c is a mitochondrial-derived peptide that the cell releases under metabolic stress to restore energy balance and reduce oxidative damage. The peptide is encoded within the mitochondrial 12S rRNA gene, not the nuclear genome, making it part of a small family of signaling molecules called mitochondrial-encoded peptides (Benayoun et al., 2019). Blood levels fall with age, which has led researchers to explore MOTS-c for age-related metabolic disorders such as obesity, type 2 diabetes and osteoporosis (Zheng et al., 2023).
The peptide being studied in labs is identical to the human sequence. Unlike large protein drugs, MOTS-c’s 16-amino-acid size may allow multiple routes of administration, but no dosage form has been approved or standardized.
💡 Definition in 60 words
MOTS-c is a 16-amino-acid mitochondrial-derived peptide produced from the 12S rRNA gene. During metabolic stress it moves into the cell nucleus and turns on genes that increase energy expenditure, improve insulin sensitivity and limit oxidative damage. All current data come from animal or cell studies; no MOTS-c drug is FDA-approved or commercially marketed.
How MOTS-c Works in the Body
The peptide boosts AMPK, a metabolic “master switch,” and shifts cells toward using glucose more efficiently. In skeletal muscle, MOTS-c blocks the folate cycle and purine synthesis, a chain reaction that activates AMPK and improves insulin signaling (Lee et al., 2015). The peptide can also travel into the nucleus and directly regulate antioxidant genes, protecting cells from oxidative stress (Li et al., 2025).
Key proposed mechanisms:
- AMPK activation: increases glucose uptake and fatty-acid oxidation (Lee et al., 2015).
- Nuclear gene regulation: up-regulates antioxidant response elements such as NQO1 and HMOX1, limiting inflammation and cell damage (Li et al., 2025).
- Thermogenesis boost: MOTS-c increases energy expenditure in white adipose tissue, mimicking some benefits of exercise (Yoon et al., 2022).
| Target tissue | Observed effect in preclinical studies | Citation |
|---|---|---|
| Skeletal muscle | Improved insulin sensitivity, higher glucose uptake | (Lee et al., 2015) |
| White adipose tissue | Increased thermogenesis, higher energy expenditure | (Yoon et al., 2022) |
| Endothelial cells (lung) | Reduced oxidative stress, less ischemia-reperfusion injury | (Shen et al., 2025) |
| Pancreatic β-cells (mouse GDM model) | Protection from toxin-induced injury | (Yin et al., 2022) |
What the Evidence Shows-and Does Not Show
All published efficacy data come from rodent or cell studies; no randomized human trial of MOTS-c has published results. In obese mice, MOTS-c injections prevented weight gain and blocked diet-induced insulin resistance (Lee et al., 2015). Small animal studies suggest possible benefits for osteoporosis, cardiac surgery lung injury and ovarian cancer progression (Yin et al., 2024) (Shen et al., 2025).
No human safety studies: FDA staff reviewers who analyzed the scientific literature for the Pharmacy Compounding Advisory Committee found no human safety studies of MOTS-c, and they recommended against it.
⚠️ Why that matters
Without human data, regulators cannot establish safe dosing ranges, adverse-event profiles, drug interactions or long-term effects. Anyone considering compounded MOTS-c is effectively an early adopter of an experimental therapy.
| Condition studied | Model | Reported outcome | Human data? |
|---|---|---|---|
| Diet-induced obesity | Mouse | Blocked weight gain, improved insulin sensitivity | No |
| Gestational diabetes | Mouse | Lower blood glucose, healthier offspring | No |
| Osteoporosis | Rat | Improved bone mineral density | No |
| Ovarian cancer | Cell & mouse | Inhibited tumor growth | No |
How the 2026 FDA Interim Policy Changes Access
The October 28 2026 “Interim Access Policy for Compounding Using Certain Peptides” states that FDA does not intend to enforce action against state-licensed 503A pharmacies and physicians that compound MOTS-c, BPC-157, TB-500, KPV, Semax or Epitalon, so long as they meet quality, labeling and adverse-event reporting conditions.
Key points to remember:
- Not FDA approval: The peptide remains an unapproved drug substance.
- Not on the 503A bulks list: The formal bulks-list rulemaking is separate; this is only enforcement discretion, explained further in our bulks-list explainer.
- State boards may disagree: States regulate pharmacy practice and can choose not to allow MOTS-c compounding.
- No end date: The policy is interim with no stated end date, and HHS may reconsider it if safety problems emerge.
- Research-use-only (RUO) loophole unchanged: Peptide vials labeled “not for human use” sold online remain outside both FDA drug regulation and the new policy.
For a deeper dive into how peptide rules differ from typical prescriptions, see Peptide Regulations: What Buyers Should Know.
Should you wait for a prescription-grade product or try an RUO vial?
Check the column that fits your situation:
✅ Wait for compounded MOTS-c
- Prefer provider supervision and baseline labs
- Live in a state that follows the FDA interim policy
- Can monitor for side effects and report them
- Want pharmacy-grade sterility and potency testing
🏥 Buying RUO vials is risky if you
- Have chronic conditions requiring multiple medications
- Are pregnant, breastfeeding or immunocompromised
- Cannot verify ingredient purity or endotoxin levels
- Assume “research” peptides are legally approved drugs
Legal Ways to Get MOTS-c in 2026
Under the interim policy, you will need a prescription from a licensed U.S. provider and a 503A compounding pharmacy willing to dispense MOTS-c. Providers must write a patient-specific script; bulk office-use orders are not covered.
Rx.com plans to offer prescription compounded versions of MOTS-c through U.S.-licensed providers and a licensed 503A pharmacy (coming soon). Until then, a legal prescription means working with a licensed prescriber and a state-licensed 503A pharmacy that meets the policy's conditions.
For a step-by-step overview of online peptide prescriptions, read How Online Peptide Prescriptions Work.
Why MOTS-c Is Not a Substitute for FDA-Approved Weight-Loss Drugs
FDA-approved weight-loss medications such as semaglutide and tirzepatide were tested in large phase 3 trials; MOTS-c has no human weight-loss data at all. That evidence gap means MOTS-c cannot replace approved therapies, especially when obesity-related health risks are high.
Unknowns and Potential Risks
No maximum tolerated dose has been studied in humans. That means side effects could appear only after real-world use. Theoretical concerns include:
- Immune reactions: Any injected peptide can trigger allergic responses.
- Off-target growth signals: Animal studies suggest anti-tumor effects, but long-term human cancer risk is unstudied.
- Regulatory reversal: FDA can withdraw enforcement discretion at any time, leaving patients without legal access.
- Variable potency: Compounded peptides rely on pharmacy sourcing of raw materials, which may vary in purity.
🚨 When to Contact Your Healthcare Provider
Contact your doctor immediately if you experience any of the following after starting a peptide therapy:
- Shortness of breath or chest tightness: could signal an allergic reaction.
- Rapid swelling of the face, lips or throat: possible anaphylaxis requiring emergency care.
- Severe abdominal pain or persistent nausea: untested peptides may irritate the pancreas or liver.
- Sudden dizziness or fainting: may indicate low blood pressure or heart rhythm issues.
- Unexplained bruising or bleeding: could point to platelet or clotting disorders.
- Dark urine or jaundice: early signs of liver injury.
- New or worsening mood changes: any neuroactive peptide could affect brain chemistry.
- Lump, swelling or redness at the injection site that worsens after 48 hours: may be infection.
Scientific References
- Zheng Y, Wei Z, Wang T. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Front Endocrinol (Lausanne). 2023.
- Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015.
- Benayoun BA, Lee C. MOTS-c: A Mitochondrial-Encoded Regulator of the Nucleus. Bioessays. 2019.
- Li X, Zhan F, Qiu G, et al. MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes. Redox Biol. 2025.
- Yoon TK, Lee CH, Kwon O, et al. Exercise, Mitohormesis, and Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c). Diabetes Metab J. 2022.
- Shen Z, Lu P, Jin W, et al. MOTS-c Promotes Glycolysis via AMPK-HIF-1α-PFKFB3 Pathway to Ameliorate Cardiopulmonary Bypass-induced Lung Injury. Am J Respir Cell Mol Biol. 2025.
- Yin Y, Pan Y, He J, et al. The mitochondrial-derived peptide MOTS-c relieves hyperglycemia and insulin resistance in gestational diabetes mellitus. Pharmacol Res. 2022.
- Yin Y, Li Y, Ma B, et al. Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination. Adv Sci (Weinh). 2024.
- Federal Register :: Home, Wednesday, October 28th. federalregister.gov.
Frequently Asked Questions
Is MOTS-c the same as a GLP-1 like semaglutide?
No. MOTS-c is a mitochondrial-derived signaling peptide that affects AMPK and gene expression, while GLP-1 drugs mimic an incretin hormone that boosts insulin and slows digestion. Their mechanisms and clinical evidence are entirely different.
What dose of MOTS-c should a person take?
No human dosing studies exist, so there is no evidence-based dose. Any compounded prescription is determined by the prescriber, who must balance unknown benefits against unknown risks.
Can I buy MOTS-c legally without a prescription?
Peptide vials labeled “research use only” are sold online, but they are not regulated for human injection and are outside the FDA interim policy. A legal medical supply must come from a 503A pharmacy with a prescription.
Does the interim policy guarantee that my state allows MOTS-c compounding?
No. State boards of pharmacy set their own rules. Some may follow the policy, others may prohibit MOTS-c or require additional approvals.
How is MOTS-c stored and shipped?
Storage requirements are set by the compounding pharmacy. Until an approved label exists, you must follow the pharmacy’s instructions, typically refrigeration and protection from light.
Can I combine MOTS-c with other peptides or GLP-1 drugs?
No interaction studies are available. Combining unapproved peptides with other medications could amplify unknown risks, so always discuss with a qualified healthcare provider first.
